Vismodegib and Gemcitabine Hydrochloride in Treating Patients With Advanced Pancreatic Cancer

NCT01195415 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

25

Enrollment

NIH

Sponsor class

Conditions

Recurrent Pancreatic Carcinoma
Stage IV Pancreatic Cancer

Interventions

DRUG: Gemcitabine Hydrochloride
OTHER: Laboratory Biomarker Analysis
DRUG: Vismodegib

Sponsor

National Cancer Institute (NCI)